Analystreport

Novogen (NASDAQ:KZIA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.

Kazia Therapeutics Limited - American Depositary Shares  (KZIA) 
US:NASDAQ Investor Relations: kaziatherapeutics.com